Etiology and pathogenesis of inflammatory bowel disease

Current Opinion in Gastroenterology

Volumn 13, Issue 4, 1997, Pages 302-306

  MacDermott, Richard P ^a  

^a LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; COMPLEMENT; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 2; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA;

CELL FUNCTION; ENTERITIS; GRANULOCYTE; HEALING; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; MACROPHAGE; MEDIATOR; PATHOGENESIS; SHORT SURVEY; T LYMPHOCYTE;

EID: 0030764421     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199707000-00004     Document Type: Short Survey

References (35)

1. 2 microglobulin transgenic rats. J Clin Invest 1996, 98:945-953. An outstanding study demonstrating that normal luminal bacteria, in general, and Bacteroides, in particular, predictably and uniformly will induce chronic colonic, gastric, and systemic inflammation in a transgenic animal model of chronic intestinal inflammation.
2. 1 cell activity and intestinal inflammation.
3. Herfarth HH, Mohanty SP, Rath HC, Tonkonogy S, Sartor RB: Interleukin 10 suppresses experimental chronic, granulomatous inflammation induced by bacterial cell wall polymers. Gut 1996, 39:836-845. A useful study demonstrating the effectiveness of interleukin-10 treatment in an exogenoulsy induced animal model of chronic granulomatous intestinal inflammation.
4. Neurath MF, Pettersson S, zum Buschenfelde KHM, Strober W: Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nature Med 1996, 2:998-1004, A novel approach to treating both exogenously induced as well as genetic knockout animal models of intestinal inflammation using antisense oligonucleotides against the transcription factor NF-κB p65.
5. Mizoguchi A, Mizoguchi E, Chiba C, Spiekermann GM, Tonegawa S, Nagler-Anderson C, Bhan AK: Cytokine imbalance and autoantibody production in T cell receptor-α mutant mice with inflammatory bowel disease. J Exp Med 1996, 183:847-856. An outstanding study examining ulcerative colitis-like colonic inflammation in mice mutant for the T-cell receptor alpha gene in which autoantibodies against tropomyosin are demonstrated.
6. + cells. Am J Pathol 1996, 148:1503-1515. A valuable study describing the histopathologic alterations present in the inflamed intestines of a mouse model created by the transfer of a subset of highly activated T-cells into severe combined immunodeficient mice.
7. Ward JM, Anver MR, Haines DC, Melhorn JM, Gorelick P, Yan L, Fox JG: Inflammatory large bowel disease in immunodeficient mice naturally infected with Helicobacter hepaticus. Lab Anim Sci 1996, 46:15-20. An intriguing study demonstrating Helicobacter hepaticus infection as a causative factor in colonic inflammation in immunodeficient mice.
8. + T-cell clones in patients with ulcerative colitis.
9. Gulwani-Akolkar B, Akolkar PN, Minassian A, Pergolizzi R, McKinley M, Mullin G, Fisher S, Silver J: Selective expansion of specific T cell receptors in the inflamed colon of Crohn's disease. J Clin Invest 1996, 98:1344-1354. An important study that demonstrates a highly restricted T-cell response in Crohn's disease patients.
10. Nielsen OH, Koppen T, Rudiger N, Horn T, Eriksen J, Kirman I: Involvement of interleukin-4 and -10 in inflammatory bowel disease. Dig Dis Sci 1996, 41:1786-1793. An interesting study that demonstrates decreased suppressor cytokine mRNA expression in ulcerative colitis and Crohn's disease patients.
11. Daig R, Andus T, Aschenbrenner E, Falk W, Scholmerich J, Gross V: Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease. Gut 1996, 38:216-222. A useful study demonstrating an excellent correlation between mucosal mRNA expression of interleukin-8 with mucosal interleukin-8 protein levels, and with histologic amounts of intestinal inflammation.
12. Grimm MC, Elsbury SKO, Pavli P, Doe WF: Interleukin 8: cells of origin in inflammatory bowel disease. Gut 1996, 38:90-98. A solid study showing that neutrophils and macrophages are responsible for the production of interleukin 8 in IBD.
13. Mazzucchelli L, Hauser C, Zgraggen K, Wagner HE, Heiss MW, Laissue JA, Mueller C: Differential in situ expression of the genes encoding the chemokines MCP-1 and RANTES in human inflammatory bowel disease. J Pathol 1996, 178:201-206. An interesting study demonstrating increased numbers of MCP-1 and RANTES mRNA-expressing cells in the mucosa of patients with IBD.
14. McKenzie SJ, Baker MS, Buffinton GD, Doe WF: Evidence of oxidant-induced injury to epithelial cells during inflammatory bowel disease. J CIm Invest 1996, 98:136-141. An excellent study providing clear evidence of reactive oxygen-nitrogen species-induced injury to the intestine in IBD.
15. Valentine JF, Tannahill CL, Stevenot SA, Sallustio JE, Nick HS, Eaker EY: Colitis and interleukin 1b up-regulate inducible nitric oxide synthase and Superoxide dismutase in rat myenteric neurons. Gastroenterology 1996, 111:56-64. An intriguing study that begins to outline the molecules involved m inducing as opposed to protecting against nitric oxide cytotoxicity in experimental colitis.
16. Finch PW, Pricolo V, Wu A, Finkelstein SD: Increased expression of keratinocyte growth factor messenger RNA associated with inflammatory bowel disease. Gastroenterology 1996, 110:441-451. A valuable study showing increased expression of keratinoctye growth factor mRNA in human inflamed IBD tissue.
17. Zeeh JM, Procaccino F, Hoffmann P, Aukerman SL, McRoberts JA, Soltani S, Pierce GF, Lakshmanan J, Lacey D, Eysselem VE: Keratinocyte growth factor ameliorates mucosal injury in an experimental model of colitis in rats. Gastroenterology 1996, 110:1077-1083. A provocative study demonstrating that administration of keratinocyte growth factor could reduce ulcerations and intestinal inflammation in an exogenously induced animal model of colitis.
18. Babyatsky MW, Rossiter G, Podolsky DK: Expression of transforming growth factors α and β in colonic mucosa in inflammatory bowel disease. Gastroenterology 1996, 110:975-984. An intriguing study demonstrating enhanced expression of transforming growth factors in IBD, suggesting that they may play a role in the promotion of healing and enhancement of mucosal restitution.
19. Razi-Wolf Z, Hollander GA, Reiser H: Activation of CD4+ T lymphocytes from interleukin 2-deficient mice by costimulatory B7 molecules. Proc Natl Acad Sci U S A 1996, 93:2903-2908.
20. +-cell depleted, athymic and NK-cell depleted SCID mice. Inflamm Res 1996, 45:181-191.
21. Elson CO, Beagley KW, Sharmanov AT, Fujihashi K, Kiyono H, Tennyson GS, Cong Y, Black CA, Ridwan BW, McGhee JR: Hapten-induced model of murine inflammatory bowel disease. Mucosal immune responses and protection by tolerance. J Immunol 1996, 157:2174-2185.
22. Soderstrom K, Bucht A, Halapi E, Gronberg A, Magnusson I, Kiessling R: Increased frequency of abnormal gd T cells in blood of patients with inflammatory bowel diseases. J Immunol 1996, 156:2331-2339.
23. Duchmann R, Hermann EM, zum Buschenfelde KHM: Bacteria-specific T-cell clones are selective in their reactivity towards different enterobacteria or H. pylori and increased in inflammatory bowel disease. Scand J Immunol 1996, 44:71-79.
24. Monajemi H, Meenan J, Lamping R, Obradov DO, Radema SA, Trown PW, Tytgat GN, VanDeventer SJH: Inflammatory bowel disease is associated with increased mucosal levels of bactericidal/permeability-increasing protein. Gastroenterology 1996, 110:733-739.
25. Stoffel MP, Csernok E, Herzberg C, Johnston T, Carroll SF, Gross WL: Anti-neutrophil cytoplasmic antibodies (ANCA) directed against bactericidal/permeability increasing protein (BPI): a new seromarker for inflammatory bowel disease and associated disorders. Clin Exp Immunol 1996, 104:54-59.
26. Nielsen OH, Brynskov J, Vainer B: Increased mucosal concentrations of soluble intercellular adhesion molecule-1 (slCAM-1), sE-selectin, and interleukin-8 in active ulcerative colitis. Dig Dis Sci 1996, 41:1780-1785.
27. Kirman I, Nielsen OH: LFA-1 subunit expression in ulcerative colitis patients. Dig Dis Sci 1996, 41:670-676.
28. Loguercio C, D'Argenio G, Cave MD, Cosenza V, Valle ND, Mazzacca G, Blanco CDV: Direct evidence of oxidative damage in acute and chronic phases of experimental colitis in rats. Dig Dis Sci 1996, 41:1204-1211.
29. Lih-Brody L, Powell SR, Collier KP, Reddy GM, Cerchia R, Kahn E, Weissman GS, Katz S, Floyd RA, McKinley MJ, Fisher SE, Mulin GE: Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease. Dig Dis Sci 1996, 41:2078-2086.
30. Sartor RB, DeLaCadena RA, Green KD, Stadnicki A, Davis SW, Schwab JH, Adam AA, Raymond P, Colman RW: Selective kallikrein-kinin system activation in inbred rats differentially susceptible to granulomatous enterocolitis. Gastroenterology 1996, 110:1467-1481.
31. Stadnicki A, DeLaCadena RA, Sartor RB, Bender D, Kettner CA, Rath HC, Adam A, Colman RW: Selective plasma kallikrein inhibitor attenuates acute intestinal inflammation in lewis rat. Dig Dis Sci 1996, 41:912-920.
32. Mishina D, Katsel P, Brown ST, Gilberts E CAM, Greenstein Rj: On the etiology of Crohn's disease. Proc Natl Acad Sci U S A 1996, 93:9816-9820.
33. Dumonceau JM, Vanossum A, Adler M, Fonteyne PA, Vanvooren JP, Deviere J, Porteais F: No Mycobacterium paratuberculosis found in Crohn's disease using the polymerase chain reaction. Dig Dis Sci 1996, 41:421-426,
34. Walmsley RS, Ibbotson JP, Chahal H. Allan RN: Antibodies against Mycobacterium paratuberculosis in Crohn's disease. Q J Med 1996, 89:217-221.
35. MacDermolt RP: Inflammatory bowel disease [commentary]. Curr Opin Gastroenterol 1994, 10:355-357.